<DOC>
	<DOCNO>NCT01620229</DOCNO>
	<brief_summary>This phase I/II trial study side effect best way give brentuximab vedotin see well work donor stem cell transplant treat patient hematologic malignancy . Monoclonal antibody , brentuximab vedotin , block cancer growth different way . Some block ability cancer grow spread . Others find cancer cell help kill carry cancer-killing substance . Monoclonal antibody may kill cancer cell leave donor stem cell transplant .</brief_summary>
	<brief_title>Brentuximab Vedotin After Donor Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine incidence durable donor hematopoietic engraftment ( define donor T-cell chimerism &gt; 50 % day +84 hematopoietic cell transplantation [ HCT ] ) allogeneic HCT post-transplant brentuximab vedotin . SECONDARY OBJECTIVES : I . Rates complete partial response ; incidence acute graft-versus-host disease ( GVHD ) grade II-IV chronic GVHD ; overall progression-free survival ; rate serious adverse event associate brentuximab vedotin . OUTLINE : Patients receive brentuximab vedotin intravenously ( IV ) day 1 . Treatment repeat every 21 day 16 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 5 year .</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients must cluster differentiation ( CD ) 30+ malignancy , CD30 positivity demonstrate either time original diagnosis subsequent time point Patients must undergo allogeneic HCT relate unrelated donor ; acceptable donor include : Related donor : genotypically phenotypically identical serological type human leukocyte antigen ( HLA ) A , B , C , allele level DRB1 DQB1 Unrelated donor : Fred Hutchinson Cancer Research Center ( FHCRC ) matching allow grade 1.0 2.1 : match HLAA , B , C , DRB1 DQB1 highresolution type For donor , single allele disparity allow HLAA , B , C define highresolution type Patients HLAhaploidentical donor eligible Patients must document posttransplant donor CD3+ chimerism &gt; 50 % sort peripheralblood CD3+ cell Patients must least 28 day allogeneic HCT time enrollment ; general , patient 60 day allogeneic HCT time enrollment ; however , patient 60 day allogeneic HCT may consider enrollment discussion protocol investigator ( Dr. Maloney ) Patients must enrol FHCRC nonmyeloablative allogeneic transplant protocol ( standard treatment plan ) ; eligibility purpose , `` nonmyeloablative '' define condition therapy consist = &lt; 4 Gy total body irradiation , without fludarabine Patients prior exposure brentuximab vedotin eligible enrollment trial , regardless previous disease response Women childbearing age men female partner childbearing age must willing able use effective method contraception study least 30 day last study dose brentuximab vedotin Patients must able give informed consent Patients seropositive human immunodeficiency virus ( HIV ) Women pregnant breastfeeding Patients moderate severe peripheral neuropathy ( grade 2 high ) ; patient history moderate/severe peripheral neuropathy may enrol neuropathy improves = &lt; grade 1 time enrollment Patients significant hepatic dysfunction , manifest total serum bilirubin &gt; 4.0 g/dL ; clinical evidence decompensated hepatic failure ; clinical evidence decompensated portal hypertension Patients absolute neutrophil count &lt; 1,000 cells/mm^3 Patients Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 Patients serum creatinine &gt; 3.0 mg/dL Patients know hypersensitivity brentuximab vedotin excipient contain drug formulation Patients currently receive treatment systemic antineoplastic investigational agent target CD30+ hematologic malignancy Patients active uncontrolled infection respond appropriate treatment discuss study investigator ( Dr. Maloney ) enrollment Patients receive donor lymphocyte infusion low donor chimerism pending graft rejection eligible</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>